<DOC>
	<DOCNO>NCT00790127</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability HQK-1001 administer daily 8 week subject beta thalassemia intermedia</brief_summary>
	<brief_title>Phase 1/2 Study HQK-1001 Patients With Beta Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Clinical diagnosis beta thalassemia intermedia hemoglobin E beta thalassemia Average initial two hemoglobin level less 10 g/dL within ≥ 30 day prior randomization . Age ≥ 12 ≤ 60 year Able willing give inform consent assent ( less 18 year age ) comply study procedure If female childbearing potential , must document negative pregnancy test Day 1 must agree use one locally medically accept method contraception month prior randomization , entire study , 4 week last dosing study medication Spleen palpable ≥ 2 cm leave costal margin Pulmonary hypertension require oxygen therapy QTc &gt; 450 msec screen ECG Infection hepatitis C , hepatitis B require therapy Known infection HIV Red blood cell ( RBC ) transfusion within 2 month prior administration study medication stable hemoglobin level Fever great 38.5°C week prior administration study medication ALT &gt; 4x upper limit normal ( ULN ) Baseline elevation CPK value prior randomization Treatment hydroxyurea within 2 month prior administration study medication Cancer diagnosis within 5 year randomization ( except nonmelanoma cutaneous malignancy ) Serum creatinine &gt; 1.5 mg/dl Received investigational systemic therapy within 30 day prior randomization Currently pregnant breast feeding child Subject history clinically significant arrhythmias syncope Known current drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>